Jan 10, 2022 / 02:00PM GMT
Christopher Thomas Schott - JPMorgan Chase & Co, Research Division - Senior Analyst
Good morning, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be introducing Coherus this morning at the 40th Annual JPMorgan conference. For the company, we have Denny Lanfear, the President and CEO.
And before I turn it over to Denny, I do want to remind everybody that if you want to ask a question, feel free to use the Ask a Question feature on the website, I'll work those into the Q&A post the presentation.
With that, Denny, happy new year. Thanks for joining us and look forward to the presentation.
Dennis M. Lanfear - Coherus BioSciences, Inc. - Chairman, President & CEO
Chris, and thank you once again for your kind invitation to this year's JPMorgan conference. Sorry that we couldn't be with you in person.
Let me first apprise you, of course, of the forward-looking statements and direct the audience to the requisite SEC filings with respect to each of the company's products including UDENYCA, YUSIMRY et al. Let me
Coherus BioSciences Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 10, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers